Put companies on watchlist
SARTORIUS AG
ISIN: DE0007165607
WKN: 716560
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

SARTORIUS AG · ISIN: DE0007165607 · EQS - Company News (39 News)
Country: Germany · Primary market: Germany · EQS NID: 1838357
16 February 2024 10:00AM

Sartorius releases Annual Report for 2023


EQS-News: SARTORIUS AG / Key word(s): Annual Report
Sartorius releases Annual Report for 2023 (news with additional features)

16.02.2024 / 10:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Göttingen, February 16, 2024 
Sartorius releases Annual Report for 2023

The life science group Sartorius has released its Annual Report for 2023 today. The document is available under the following link: https://ir-reports.sartorius.com/en/ag/fy-2023


Financial calendar 
March 28, 2024     Annual General Meeting
April 18, 2024       Publication of first-quarter figures (January to March 2024)
July 19, 2024        Publication of first-half figures (January to June 2024)
October 17, 2024     Publication of nine-month figures (January to September 2024)


A profile of Sartorius 
Sartorius is a leading international partner of life sciences research and biopharmaceutical manufacturing. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2023, the company generated sales revenue of around 3.4 billion euros. Currently, around 14,600 employees are working for customers around the globe.


Contact
Timo Lindemann
External Communications
+49 (0)551.308.4724
timo.lindemann@sartorius.com

Follow Sartorius on LinkedIn.

Additional features:

File: Press Release


16.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SARTORIUS AG
Otto-Brenner-Straße 20
37079 Göttingen
Germany
Phone: +49.(0)551-308.0
Fax: +49.(0)551-308.3289
E-mail: info@sartorius.com
Internet: www.sartorius.com
ISIN: DE0007165607, DE0007165631
WKN: 716560 , 716563
Indices: DAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1838357

 
End of News EQS News Service

1838357  16.02.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1838357&application_name=news&site_id=boersengefluester_html
Visual performance / price development - SARTORIUS AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.